Forest lines up products to fill Lexapro gap as Linzess and Tudorza launched in US
This article was originally published in Scrip
Loss of patent protection for the depression and anxiety drug Lexapro (escitalopram oxalate) continues to eat away Forest Laboratories' earnings, but the New York-based company is working to replace revenue from the selective serotonin reuptake inhibitor (SSRI) with sales from new products, including the irritable bowel syndrome (IBS) therapy Linzess (linaclotide) that launched in partnership with Ironwood Pharmaceuticals in December.
You may also be interested in...
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.
Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.